# Xynomic Pharmaceuticals

Source: https://onco.cc/companies/xynomic-pharmaceuticals/  
OnCo record `xynomic-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Xynomic Pharmaceuticals is a Chinese-American biotech that licensed the histone deacetylase inhibitor abexinostat from Pharmacyclics and is testing it with pazopanib in kidney cancer and alone in lymphoma.

## Summary

Xynomic Pharmaceuticals is an oncology company with operations in Zhongshan, Guangdong and the San Francisco Bay Area. Its lead asset is abexinostat, a pan-histone deacetylase inhibitor in-licensed from Pharmacyclics (now part of AbbVie), which it has taken into a phase 3 trial with pazopanib in renal cell carcinoma and into follicular lymphoma studies in China. It also holds rights to the pan-RAF inhibitor XP-102 and other clinical-stage assets.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Xynomic Pharmaceuticals Holdings; Xynomic Pharma
- Tags: drug-maker
- HQ: Zhongshan
- Type: biotech
- Website: https://www.xynomicpharma.com/

## Sources

- Official website: https://www.xynomicpharma.com/

## Connected records

- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/)
- trials: [A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients](https://onco.cc/trials/nct04024696/), [A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma](https://onco.cc/trials/nct03934567/), [A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)](https://onco.cc/trials/renaviv/), [Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma](https://onco.cc/trials/nct03600441/), [Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)](https://onco.cc/trials/nct03936153/), [XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation](https://onco.cc/trials/nct05275374/)

---
JSON: https://onco.cc/api/v1/entities/xynomic-pharmaceuticals.json